COMPAZINE
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Jun 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is an oral extended-release capsule small molecule approved in 1957 as a typical antipsychotic and antiemetic agent. The drug is primarily used for nausea, vomiting, and psychiatric indications, working through dopamine antagonism in the chemoreceptor trigger zone and central nervous system. It represents a legacy product from GSK's portfolio with decades of clinical use.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting commercial team focused on managed decline and retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on COMPAZINE offers limited career growth due to approaching loss of exclusivity and minimal linked job openings (0 identified). Roles focus on managed decline, compliance, and maintaining existing market share rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.